TYK MEDICINES-B(02410) and Sichuan Huiyu have entered into a potential exclusive distribution agreement for TY-9591.

TYK MEDICINES-B (02410) announcement states that Sichuan Huiyu Pharmaceutical Co., Ltd. (Sichuan Huiyu) published a notice on August 26, 2025, regarding its board of directors approving a potential exclusive agency agreement for TY-9591 (the core product of the company) with Sichuan Huichenxin Pharmaceutical Co., Ltd. (Sichuan Huichenxin, a wholly-owned subsidiary of Sichuan Huiyu). According to the potential exclusive agency agreement, the company can appoint Sichuan Huichenxin as the exclusive distributor of TY-9591 in China (excluding Hong Kong, Macao, Taiwan, and any other overseas areas), with an initial milestone payment of up to RMB 150 million. The company is about to enter the commercialization stage of TY-9591, and if the potential exclusive agency agreement is implemented, the company will be able to leverage the extensive sales and distribution network of Sichuan Huichenxin and Sichuan Huiyu. Sichuan Huiyu is a mature pharmaceutical company with a complete industry chain and extensive experience in drug distribution and sales in China. Therefore, the company believes that this arrangement will help increase the sales and revenue of TY-9591, accelerate market penetration, reduce the cost of establishing new sales channels for the company, and strengthen the company's brand image through cooperation with well-known pharmaceutical companies.